Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jan 1;5(2):305-311.

Malignant Ascites Associated with Carcinoma of the Prostate

Muhammad Wasif Saif  1
Affiliations

Malignant Ascites Associated with Carcinoma of the Prostate

Muhammad Wasif Saif. J Appl Res. .

Abstract

BACKGROUND: Prostate cancer is the most common malignancy in men in the United States. Both at diagnosis and throughout the disease progression, it can metastasize to multiple organs, most commonly bone and lymph nodes. Effusions (either pleural or abdominal) are relatively uncommon. PATIENTS AND METHODS: We reviewed the medical literature including the case reports and post-mortem studies relating ascites to prostate cancer, identified through a MEDLINE search (human; all languages; 1969-2004). RESULTS: We found 12 published cases. Forty two percent of patients presented initially with ascites, in 50% ascites developed later with progressive disease, and 8% had ascites being the only site of recurrence. The response rate to endocrine therapy, including orchiectomy, was 25%. Ascites in these patients conferred a poorer prognosis. CONCLUSION: The development of ascites secondary to prostate cancer, either as an initial manifestation or recurrent disease, is not well known and may be unfamiliar to many physicians. If patients with history of prostate cancer develop malignant effusions, prostate specific antigen (PSA) immunohistostaining of the fluid can serve as a valuable adjunctive study for the diagnosis. This clinical situation becomes particularly important in patients with ascites with a carcinoma of unknown primary. Palliation can be achieved in patients with ascites secondary to prostate cancer using hormone manipulation. Lack of knowledge about this complication of prostate cancer may delay the diagnosis and treatment of this hormonally responsive malignancy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Papinacolou stain showing malignant cells in peritoneal fluid.
Figure 2
Figure 2
Positive staining with prostate specific antigen of the peritoneal fluid.
Figure 3
Figure 3
Positive prostatic acid phosphatase staining of the peritoneal fluid.
See this image and copyright information in PMC

References

    1. American Cancer Society. Cancer Facts and Figures 2004. Atlanta, Ga: American Cancer Society; 2004.
    1. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med. 1993;118(10):804–818. - PubMed
    1. Helgesen F, Holmberg L, Johansson JE, et al. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst. 1996;88(17):1216–1221. - PubMed
    1. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–2246. - PubMed
    1. Gittes RF. Carcinoma of the prostate. N Engl J Med. 1991;324(4):236–245. - PubMed

LinkOut - more resources